Angiotensin-converting enzyme gene polymorphism is associated with anemia in non-small-cell lung cancer

Experimental Biology and Medicine

Volumn 233, Issue 1, 2008, Pages 32-37

  Yaren, Arzu ^a,c   Oztop, Ilhan ^b   Turgut, Sebahat ^a   Turgut, Gunfer ^a   Degirmencioglu, Serkan ^a   Demirpence, Mustafa ^b  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c Department of Physiology ^*  (Turkey)

Author keywords

Anemia; Angiotensin converting enzyme gene polymorphism; Non small cell lung cancer

Indexed keywords

ADULT; AGE DISTRIBUTION; ALLELE; ANEMIA; ANGIOTENSIN CONVERTING ENZYME GENE; ARTICLE; BLOOD SAMPLING; COMPUTER PROGRAM; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE DELETION; GENE INSERTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEX RATIO; STATISTICAL ANALYSIS;

ALLELES; ANEMIA; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; ERYTHROPOIETIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RENIN;

EID: 37549067373     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0705-RM-141     Document Type: Article

References (40)

1. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990.
2. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293-299, 2005.
3. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67-75, 2003.
4. Gonzalez-Zuloeta Ladd AM, Vasquez AA, Tabatabaei FAS, Coebergh JW, Hofman A, Njajou O, Stricker B., van Dujin C. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:2143-2146, 2005.
5. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 63:573-578, 2003.
6. Röcken C, Lendelkel U, Dierkes J, Westphal S, McGrath SC, Peters B, Krüger S, Malfertheiner P, Roessner A, Ebert MPA. The number of the lymph node metastasis in gastric cancer correlates with the Angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 11:2526-2530, 2005.
7. Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, Lopes C. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol 202:330-335, 2004.
8. Usmani BA, Janeczko M, Shen R, Mazumdar M, Papandreou CN, Nanus DM. Analysis of the insertion/deletion polymorphism of the human angiotensin-converting enzyme (ACE) gene in patients with renal cancer. Br J Cancer 82:550-552, 2000.
9. Cheon KT, Choi KH, Lee HB, Park SK, Rhee YK, Lee YC. Gene polymorphism of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 178:351-360, 2000.
10. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 25:2-6, 1998.
11. Mercadante S, Gebbia V, Marrazzo A. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26:303-311, 2000.
12. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214-2221, 2001.
13. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systemic review of the literature. Am J Med 116:11S-26S, 2004.
14. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991.
15. Aoe K, Hiraki A, Maeda T, Katayama H, Fujiwara K, Tabata M, Kiura K, Ueoka H, Tanimoto M. Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer. Intern Med 44:800-804, 2005.
16. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100:2310-2314,1997.
17. Rodgers KE, Xiong S, Steer R, DiZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 18:287-294, 2000.
18. Vasku A, Soucek M, Znojil V, Rihacek I, Cidl K, Strelcova L, Vacha J. Does angiotensin I-converting enzyme inhibitor therapy have an antiproliferative effect on blood-forming bone marrow? Exp Hematol 26:277-279, 1998.
19. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol 354:179-187, 1998.
20. Morrone LF, Di Paolo S, Logoluso F, Schena A, Stallone G, Giorgino F, Schena FP. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 64:913-918, 1997.
21. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 84:876-882, 1999.
22. Haznedaroglu IC, Arici M, Buyukasik Y. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses 54:80-83, 2000.
23. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappa B through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 86:1266-1272, 2000.
24. Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S. NF-kappa B activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34;1609-1621, 2002.
25. Sayeski PP, Ali MS. The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Exp Cell Res 287:339-349, 2003.
26. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int 23:111-115, 2003.
27. Girndt M, Heine GH, Kohler H. Gene polymorphism association studies in dialysis: anemia and host immunity. Semin in Dial 19:227-231, 2006.
28. Poncz M, Solowiejczyk D, Harpel B, Mory Y, Schwartz E, Surrey S. Construction of human gene libraries from small amounts of periferal blood: analysis of beta-like globin genes. Hemoglobin 6:27-36, 1982.
29. Ebert MPA, Lendelkel U, Westphal S, Dierkes J, Glas J, Folwaczny C, Roessner A, Stolte M, Malfertheiner P, Röcken C. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 14:2987-2989, 2005.
30. Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients with on continuous ambulatory peritoneal dialysis. Perit Dial Int 26:64-68, 2006.
31. Gossmann J, Thurmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, Scheuermann EH. Mechanism of angiotensin-converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50:973-978, 1996.
32. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. J Clin Invest 93:788-798,1994.
33. Volkov L, Quere P, Coudert F, Comte L, Praloran V. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines. Exp Cell Res 223:112-116, 1996.
34. Azizi M, Junot C, Ezan E, Menard J. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyllysylproline. Clin Exp Pharmacol Physiol 28:1066-1069, 2001.
35. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl- lysyl-proline. J Clin Invest 97:839-844, 1996.
36. Comte L, Lorgeot V, Volkov L, Allegraud A, Aldigier JC, Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest 27:788-790, 1997.
37. Perazelle M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy indepentent of circulating erthropoetin levels. Am J Kidney Dis 26:495-500, 1995.
38. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in haemodialysis patients. Am J Nephrol 4:355-360, 1984.
39. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100:474-482, 2002.
40. Allen DA, Bren C, Yaqoob MM, Mcdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 47:204-211, 1999.